Figure 5.

Evaluation of value of TMErisk in predicting immunotherapeutic response and validation of predictive value of TMErisk for immunotherapy in external cohorts

(A) Difference of TIDE score between the low- and high-TMErisk groups was examined by Wilcoxon test.

(B) Difference of TMB between the low- and high-TMErisk groups was examined by Wilcoxon test. Kaplan–Meier analyses for OS and PFS based on TMErisk strata in OAK cohorts (C-D, G-H), POPLAR cohort (K-L) and IMvigor210 cohort (O-P). Stacked percentage bar charts show the association of TMErisk with ORR and DCR in in OAK cohorts (E-F, I-J), POPLAR cohort (M−N) and IMvigor210 cohort (Q-R). TIDE, tumor immune dysfunction and exclusion; TMB, tumor mutation burden; HR, hazard ratio; CI, confidence interval; BOR, best overall response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate. See also Figures S10 andS11.